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Purpose
Human Parvovirus B19 causes a self-limited febrile illness
with a characteristic exanthem and occasional acute
arthritis. B19 infection has also been associated with multi-
ple rheumatic diseases. Reports indicate that in patients
with positive B19 PCR up to ~1/3 have negative IgM and
positive IgG to B19. However little is known about how
these findings might relate to rheumatologic symptoms,
especially in children.
Methods
The records of 9 patients presenting to a pediatric rheu-
matology clinic with acute onset arthralgia or arthritis and
positive B19 PCR from 2007-9 were examined retrospec-
tively. Demographic information, clinical course, physical
exam, and laboratory data including B19 serology were
recorded. The IgM-positive subgroup was compared to
the IgM-negative subgroup for differences in any of the
other variables by the two sided Fisher exact test or inde-
pendent t-test.
Results
The 9 children’s (3M:6F) ages ranged from 7-19 years.
Presenting signs included arthralgia (100%), polyarthritis
(67%) and enthesitis (22%). Presenting laboratory findings
included elevated ESR and CRP (both 78%), positive ANA
(33%), positive dsDNA (11%), RF (22%), APL antibodies
(22%), and low C4 (11%). Six infected patients (66%)
otherwise met classification criteria for systemic JIA (2),
enthesitis-related arthritis (2), RF negative polyarticular
JIA (1), or SLE (1). Patients’ B19 serology included 8 (89%)
with positive IgG of which 4 (44%) had positive IgM. Five
patients had negative IgM [1 each with SLE, enthisitis
related arthritis (ERA), polyarticular JIA, and 2 systemic
JIA]. Compared to patients with positive B19 IgM, those
with negative IgM had higher ESR at presentation (mean
+SD 82.4 + 53 vs. 10.7+9.3, p=0.04), trend to higher CRP
values (91.4+ 85.1 vs. 5.7+8.5, p=0.09), and were more
likely to be treated with steroids (p=0.04). In 6 patients
(67%) the positive B19 PCR was not found to persist past
1 month and other clinical and laboratory findings
resolved in <6 months. In the remaining 3 (1 each with
polyarticular JIA, SLE, and ERA), the illness persisted past
6 months. The patient with SLE continues with a positive
ANA years after presentation, although B19 PCR resolved
in 6 months and both APL and dsDNA antibodies
resolved within 1 year. In the patient with polyarticular
JIA B19 PCR was still positive 3 months after presentation.
Although her symptoms resolved quickly her inflamma-
tory markers continued to be elevated. The patient with
ERA is still being followed for his illness, now >6 months
into disease. He still has enthesitis and is B27 positive but
all other labwork is normal.
Conclusion
Evidence of active B19 infection may be found in children
with symptoms that mimic a variety of pediatric rheuma-
tologic diseases, including systemic and polyarticular JIA,
ERA, and SLE. Despite this, without persistence of positive
B19 PCR, symptoms resolve relatively rapidly. However,
persistence of B19 viremia may correlate with prolonged
symptomatology and more aggressive treatment. Further-
more children with positive B19 PCR and negative IgM
antibodies may have increased risk of a more severe pre-
sentation. Therefore obtaining and following B19 PCR is
essential in suspected cases.
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